Chen L, Smith DA, Somarouthu B, Gupta A, Gilani KA, Ramaiya NH. A radiologist’s guide to the changing treatment paradigm of advanced non-small cell lung cancer: the ASCO 2018 molecular testing guidelines and targeted therapies. Am J Roentgenol. 2019;213(5):1047–58.
Conde E, Rojo F, Gómez J, et al. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. J Clin Pathol. 2022;75(3):145–53.
American Lung Association. State of Lung Cancer 2020 report. Chicago IAJ, 2022. https://www.lung.org/getmedia/381ca407-a4e9-4069-b24b-195811f29a00/solc-2020-report-final.pdf.
Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non–small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040–91.
Tan AC, Tan DS. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40(6):611–25.
Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(5):497–530.
Montero MA, Aricak O, Kis L, et al. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer. Ann Diagn Pathol. 2021;51: 151701.
Page RD, Drusbosky LM, Dada H, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(1):72–81.
Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
Zer A, Cutz JC, Sekhon H, et al. Translation of knowledge to practice—improving awareness in NSCLC molecular testing. J Thorac Oncol. 2018;13(7):1004–11.
John A, Yang B, Shah R. Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced non-small cell lung cancer (aNSCLC) using real-world electronic health record data. Adv Ther. 2021;38(3):1552–66.
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46.
Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review. JAMA. 2019;322(8):764–74.
Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16(6):341–55.
Makarem M, Ezeife DA, Smith AC, et al. Reflex ROS1 IHC screening with FISH confirmation for advanced non-small cell lung cancer—a cost-efficient strategy in a public healthcare system. Curr Oncol. 2021;28(5):3268–79.
Steeghs EMP, Groen HJM, Schuuring E, et al. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer. 2022;167:87–97.
Paz-Ares L, Gondos A, Saldana D, et al. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study. Lung Cancer. 2022;167:41–8.
Tongbai T, McDermott S, Fintelmann FJ, Price MC, Sharma A, Gilman MD. Complications and accuracy of computed tomography-guided transthoracic needle biopsy in patients over 80 years of age. J Thorac Imaging. 2019;34(3):187–91.
Fintelmann FJ, Troschel FM, Kuklinski MW, et al. Safety and success of repeat lung needle biopsies in patients with epidermal growth factor receptor-mutant lung cancer. Oncologist. 2019;24(12):1570–6.
Yu TM, Morrison C, Gold EJ, Tradonsky A, Layton AJ. Multiple biomarker testing tissue consumption and completion rates with single-gene tests and investigational use of oncomine dx target test for advanced non–small-cell lung cancer: a single-center analysis. Clin Lung Cancer. 2019;20(1):20-29.e28.
Zhang Y, Shi L, Simoff MJ, Wagner OJ, Lavin J. Biopsy frequency and complications among lung cancer patients in the United States. Lung Cancer Manag. 2020;9(4):Lmt40.
Dagogo-Jack I, Azzolli CG, Fintelmann F, et al. Clinical utility of rapid EGFR genotyping in advanced lung cancer. JCO Precis Oncol. 2018;2018:1.
Roy-Chowdhuri S, Dacic S, Ghofrani M, et al. Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, America. Arch Pathol Lab Med. 2020;144(8):933–58.
Atkins L, Francis J, Islam R, et al. A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems. Implement Sci. 2017;12(1):77.
Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398–405.
Wells C, Loshak H. CADTH Rapid Response Reports. Standardized Hospital Order Sets in Acute Care: A Review of Clinical Evidence, Cost-Effectiveness, and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health
Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.; 2019.
Lim C, Sekhon HS, Cutz JC, et al. Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario. Curr Oncol. 2017;24(2):103–10.
Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res. 2019;8(3):286–301.
Sadik H, Pritchard D, Keeling D-M, et al. Impact of clinical practice gaps on the implementation of personalized medicine in advanced non–small-cell lung cancer. JCO Precis Oncol. 2022(6).
Bourgouin PP, Rodriguez KJ, Fintelmann FJ. Image-guided percutaneous lung needle biopsy: how we do it. Tech Vasc Interv Radiol. 2021;24(3): 100770.
Goiffon RJ, Best TD, Wrobel MM, et al. Reducing time and patient radiation of computed tomography-guided thoracic needle biopsies with single-rotation axial acquisitions: an alternative to “CT Fluoroscopy.” J Thorac Imaging. 2021;36(6):389–96.
Beck KS, Kim T-J, Lee KY, Kim YK, Kang JH, Han DH. CT-guided coaxial biopsy of malignant lung lesions: are cores from 20-gauge needle adequate for histologic diagnosis and molecular analysis? J Thorac Dis. 2019;11(3):753–65.
Jamshidi N, Huang D, Abtin FG, et al. Genomic adequacy from solid tumor core needle biopsies of ex vivo tissue and in vivo lung masses: prospective study. Radiology. 2016;282(3):903–12.
Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol. 2016;34(30):3638–47.
Fassina A, Corradin M, Zardo D, Cappellesso R, Corbetti F, Fassan M. Role and accuracy of rapid on-site evaluation of CT-guided fine needle aspiration cytology of lung nodules. Cytopathology. 2011;22(5):306–12.
VanderLaan PA. Percutaneous lung biopsy: point—fine-needle aspiration first. Am J Roentgenol. 2021;218(5):794–5.
Yoon HJ, Lee HY, Lee KS, et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology. 2012;265(3):939–48.
Herbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI. Practical considerations relating to routine clinical biomarker testing for non–small cell lung cancer: focus on testing for RET fusions. Front Med. 2021;7.
Levy EB, Fiel MI, Hamilton SR, et al. State of the art: toward improving outcomes of lung and liver tumor biopsies in clinical trials—a multidisciplinary approach. J Clin Oncol. 2020;38(14):1633–40.
Nandy S, Helland TL, Roop BW, et al. Rapid non-destructive volumetric tumor yield assessment in fresh lung core needle biopsies using polarization sensitive optical coherence tomography. Biomed Opt Express. 2021;12(9):5597–613.
Sung S, Heymann JJ, Crapanzano JP, et al. Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. J Am Soc Cytopathol. 2020;9(5):332–45.
Waterhouse DM, Tseng W-Y, Espirito JL, Robert NJ. Understanding contemporary molecular biomarker testing rates and trends for metastatic NSCLC among community oncologists. Clin Lung Cancer. 2021;22(6):e901–10.
Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–42.
Govindan R, Aggarwal C, Antonia SJ, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer. 2022;10(5): e003956.
Yatabe Y, Dacic S, Borczuk AC, et al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol. 2019;14(3):377–407.